TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation

被引：0
|
作者：
Villa, S. [1 ]
Pillai, M. [2 ]
Graham, D. [1 ]
Kilgour, E. [3 ]
Overton, N. [3 ]
Vasudev, N. [4 ,5 ]
Hughes, A. [6 ]
Walker, A. [1 ]
Dransfield, S. [1 ]
Thistlethwaite, F. [1 ]
机构：
[1] Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Canc Res UK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England
[4] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[5] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[6] Univ Manchester, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy315.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58TiP
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors
    Melichar, B.
    Studentova, H.
    Zezulova, M.
    JOURNAL OF BUON, 2011, 16 (02): : 203 - 209
  • [32] Turning a renal cell carcinoma with extended thrombus of the vena cava into an operable tumor by tyrosine kinase inhibitor therapy
    Siedler, M.
    Beissert, M.
    Marques-Maggio, E.
    Papoutsoglou, N.
    Loeser, A.
    Riedmiller, H.
    GEFASSCHIRURGIE, 2011, 16 (06): : 421 - 424
  • [33] Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma
    Ishikawa, Gaku
    Tamura, Keita
    Tsuchiya, Yoshihiro
    Watanabe, Shunsuke
    Ayana, Takemura
    Asuka, Sano
    Watanabe, Kyohei
    Watanabe, Hiromitsu
    Matsushita, Yuto
    Motoyama, Daisuke
    Otsuka, Atsushi
    Inamoto, Teruo
    ANTICANCER RESEARCH, 2025, 45 (01) : 379 - 386
  • [34] Evaluating response of renal cell carcinoma to tyrosine kinase inhibitor and immune checkpoint inhibitor using a human histo-culture platform
    Sankaran, Satish
    Jaganathan, Kowshik
    Gowri, Shankar K.
    Bhargav, Saurabh
    Ganesh, M. S.
    Prabha, Amritha
    Prakash, B., V
    Syamkumar, V
    Das, Biswajit
    Vasanth, K.
    Manimaran, A.
    Bhowal, Chandan
    Rajashekar, M.
    Oliyarasi, M.
    Malhotra, Ritu
    Govindraj, K.
    Basak, Nandini Pal
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC)
    Khorasanchi, Adam
    Kwok, Christopher
    Psutka, Sarah P.
    Hinkley, Megan
    Dason, Shawn
    Yang, Yuanquan
    Verschraegen, Claire F.
    Gross, Evan
    Orcutt, Delaney
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] RENAL-CELL CARCINOMA - PHYSIOLOGY, DIAGNOSIS, AND THERAPY
    ABIAAD, AS
    BELLDEGRUN, A
    DEKERNION, JB
    WORLD JOURNAL OF UROLOGY, 1991, 9 (04) : 168 - 172
  • [37] Targeted therapy for patients with renal-cell carcinoma
    Rini, Brian I.
    LANCET ONCOLOGY, 2011, 12 (12): : 1085 - 1087
  • [38] SELECTION OF INITIAL THERAPY FOR RENAL-CELL CARCINOMA
    DEKERNION, JB
    MUKAMEL, E
    CANCER, 1987, 60 (03) : 539 - 546
  • [39] CYTOKINE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    OTTO, T
    GOEPEL, M
    LUBOLDT, HJ
    RUBBEN, H
    UROLOGE-AUSGABE A, 1995, 34 (03): : 200 - 203
  • [40] Systemic Therapy for Metastatic Renal-Cell Carcinoma
    Choueiri, Toni K.
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04): : 354 - 366
12345